U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H23NO3.C4H6O4
Molecular Weight 431.4789
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESREBOXETINE SUCCINATE

SMILES

OC(=O)CCC(O)=O.[H][C@]1(CNCCO1)[C@@H](OC2=C(OCC)C=CC=C2)C3=CC=CC=C3

InChI

InChIKey=YXZTUOWIYOESGT-HLRBRJAUSA-N
InChI=1S/C19H23NO3.C4H6O4/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18;5-3(6)1-2-4(7)8/h3-11,18-20H,2,12-14H2,1H3;1-2H2,(H,5,6)(H,7,8)/t18-,19-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H23NO3
Molecular Weight 313.3908
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Esreboxetine (PNU-165442G) is the (S,S)-(+)-enantiomer of antidepressant reboxetine, a selective norepinephrine reuptake inhibitor. The (S,S)-enantiomer is a more potent inhibitor of norepinephrine transporter than (R,R)-enantiomer. Esreboxetine was being developed by Pfizer, primarily for the treatment of fibromyalgia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.08 nM [Ki]
PubMed

PubMed

TitleDatePubMed
Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.
2000 Dec
Urinary retention with reboxetine-fluoxetine combination in a young man.
2000 Dec
Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
2000 May 1
Acute akinetic crisis with marked cognitive impairment due to Valproate treatment.
2003 Apr
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
2006 Jun
[Synthetic meshes for transvaginal surgical cure of genital prolapse: evaluation in 2005].
2006 Sep
Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril.
2008
Reutilization of the Prolift mark system for the simultaneous correction of prolapse and incontinence in patients with pelvic organ prolapse and stress urinary incontinence.
2008 Nov
[Occult stress incontinence identified by preoperative urodynamic study in women with severe pelvic organ prolapse].
2008 Sep
A prospective study to evaluate the anatomic and functional outcome of a transobturator mesh kit (prolift anterior) for symptomatic cystocele repair.
2008 Sep-Oct
[Surgical treatment of female pelvic organ prolapse at the Clinic of Obstetrics and Gynecology, Hospital of Kaunas University of Medicine].
2009
[Transvaginal repair of genital prolapse with Prolift: evaluation of safety and learning curve].
2009 Feb
[Clinical observation on quality of life of two different operative methods of total pelvic floor reconstruction.].
2009 Nov
A serious complication following placement of posterior Prolift.
2009 Nov
Anatomic outcomes of vaginal mesh procedure (Prolift) compared with uterosacral ligament suspension and abdominal sacrocolpopexy for pelvic organ prolapse: a Fellows' Pelvic Research Network study.
2009 Nov
[Changes in the length of implanted mesh after reconstructive surgery of the anterior vaginal wall].
2010 Apr
[Prolene mesh comparing with sacrospinal fixation in the treatment of genital prolapse in women. Prospective multicentre randomized study].
2010 Apr
Permeation of herbicidal dichlobenil from a Casoron formulation through nitrile gloves.
2010 Feb
One-year outcome of concurrent anterior and posterior transvaginal mesh surgery for treatment of advanced urogenital prolapse: case series.
2010 Jul-Aug
Anatomical and functional outcomes of posterior intravaginal slingplasty for the treatment of vaginal vault or uterine prolapse: a prospective, multicenter study.
2010 Mar
Does trocar-guided tension-free vaginal mesh (Prolift) repair provoke prolapse of the unaffected compartments?
2010 Mar
Optimal primary minimally invasive treatment for patients with stress urinary incontinence and symptomatic pelvic organ prolapse: tension free slings with colporrhaphy, or Prolift with the tension free midurethral sling?
2010 May
Pelvic magnetic resonance imaging for assessment of the efficacy of the Prolift system for pelvic organ prolapse.
2010 Nov
[Patent for medical device: from design to marketing (example of Prolift®)].
2010 Oct
Patents

Sample Use Guides

Phase III study: 4-10 mg once daily for 14 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:32:56 GMT 2023
Edited
by admin
on Fri Dec 15 16:32:56 GMT 2023
Record UNII
XQO13W6OCH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ESREBOXETINE SUCCINATE
USAN  
USAN  
Official Name English
ESREBOXETINE SUCCINATE [USAN]
Common Name English
PNU-165442G
Code English
(+)-(2S)-2-((S)-(2-ETHOXYPHENOXY)PHENYLMETHYL)MORPHOLINE HYDROGEN BUTANEDIOATE
Systematic Name English
(S,S)-REBOXETINE SUCCINATE
Common Name English
BUTANEDIOIC ACID, COMPD. WITH (2S)-2-((S)-(2-ETHOXYPHENOXY)PHENYLMETHYL)MORPHOLINE (1:1)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Fri Dec 15 16:32:56 GMT 2023 , Edited by admin on Fri Dec 15 16:32:56 GMT 2023
Code System Code Type Description
SMS_ID
100000127897
Created by admin on Fri Dec 15 16:32:56 GMT 2023 , Edited by admin on Fri Dec 15 16:32:56 GMT 2023
PRIMARY
EVMPD
SUB34044
Created by admin on Fri Dec 15 16:32:56 GMT 2023 , Edited by admin on Fri Dec 15 16:32:56 GMT 2023
PRIMARY
EPA CompTox
DTXSID10979793
Created by admin on Fri Dec 15 16:32:56 GMT 2023 , Edited by admin on Fri Dec 15 16:32:56 GMT 2023
PRIMARY
USAN
TT-90
Created by admin on Fri Dec 15 16:32:56 GMT 2023 , Edited by admin on Fri Dec 15 16:32:56 GMT 2023
PRIMARY
ChEMBL
CHEMBL180101
Created by admin on Fri Dec 15 16:32:56 GMT 2023 , Edited by admin on Fri Dec 15 16:32:56 GMT 2023
PRIMARY
PUBCHEM
24754241
Created by admin on Fri Dec 15 16:32:56 GMT 2023 , Edited by admin on Fri Dec 15 16:32:56 GMT 2023
PRIMARY
CAS
635724-55-9
Created by admin on Fri Dec 15 16:32:56 GMT 2023 , Edited by admin on Fri Dec 15 16:32:56 GMT 2023
PRIMARY
FDA UNII
XQO13W6OCH
Created by admin on Fri Dec 15 16:32:56 GMT 2023 , Edited by admin on Fri Dec 15 16:32:56 GMT 2023
PRIMARY
NCI_THESAURUS
C87613
Created by admin on Fri Dec 15 16:32:56 GMT 2023 , Edited by admin on Fri Dec 15 16:32:56 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY